An Open-Label Extension of Two Phase 3 Studies Evaluating Long-Term Efficacy of FMX101 4% Minocycline Foam for the Treatment of Acne Vulgaris. J of Skin 2019, 3, S1. https://doi.org/10.25251/skin.3.supp.1.